Edition:
India

People: Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

27.09USD
17 Oct 2019
Change (% chg)

-- (--)
Prev Close
$27.09
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
160,140
52-wk High
$41.59
52-wk Low
$18.00

Smith, Julie 

Ms. Julie Smith is an Independent Director of the AUDENTES THERAPEUTICS, INC. Ms. Smith is the President and Chief Executive Officer of E-Scape Bio, Inc., a biotechnology company developing novel small-molecule therapeutics for inherited neurodegenerative diseases. Previously, Ms. Smith served as the President and Chief Executive Officer at Nuredis, Inc., and President and Chief Executive Officer at Raptor Pharmaceutical Corp., a public, commercial stage biopharmaceutical company focused on developing and commercializing treatments for orphan diseases, which she joined in September 2012. Prior to joining Raptor, Ms. Smith served as the Chief Commercial Officer at Enobia Pharmaceuticals until May 2012 after its acquisition by Alexion Pharmaceuticals, Inc. Previously, Ms. Smith served in positions of increasing responsibility at Jazz Pharmaceuticals, Genzyme, Novazyme and Bristol-Myers Squibb. Ms. Smith currently serves as an independent director of Exelixis. She previously served as Director on the Health and Emerging Companies Sections of the Biotechnology Industry Organization (BIO) board. Ms. Smith holds a B.S. in Biological and Nutritional Sciences from Cornell University. Our board of directors believes that Ms. Smith’s extensive executive level experience at biotechnology companies qualifies her to serve on our board of directors.

Basic Compensation

Total Annual Compensation, USD 49,375
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 250,920
Fiscal Year Total, USD 300,295

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --